Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Cambrex will expand R&D capabilities for generic active pharmaceutical ingredients (APIs) at its Paullo, Italy, facility. The project will add a 150-m2 laboratory space as well as a research staff expansion. The company currently manufactures more than 70 generic APIs to the FDA’s current Good Manufacturing Practice quality standard. Generics account for approximately 20% of Cambrex’s sales. Earlier this year the company invested $5 million in an expansion of its laboratory facilities in Karlskoga, Sweden, augmenting process development, handling of highly potent substances, and crystallization studies.
This article has been sent to the following recipient: